Research Highlight |
Featured
-
-
-
-
-
Review Article |
Current challenges in the clinical management of hypertension
Elevated blood pressure (BP) is probably the most-important, modifiable risk factor for cardiovascular disease. Dr. Ruilope discusses current controversies and challenges in the treatment of patients with arterial hypertension, including the validity of office BP measurements, appropriateness of BP targets, use of combination therapy, and patient compliance.
- Luis M. Ruilope
-
-
Review Article |
Assessment of oral antithrombotic therapy by platelet function testing
Dual and triple antiplatelet therapies prevent ischemic events in high-risk patients with coronary artery disease or during percutaneous coronary interventions, but can cause bleeding complications. In this Review, Dr. Tantry and Dr. Gurbel discuss the utility of platelet function assays for the assessment of ischemic and bleeding risk to personalize antithrombotic combination therapies.
- Udaya S. Tantry
- & Paul A. Gurbel
-
Research Highlight |
Lowering LDL cholesterol reduces atherosclerotic risk in patients with chronic kidney disease
- Gregory B. Lim
-
Research Highlight |
Is combination antithrombotic therapy safe for patients with atrial fibrillation?
- Helene Myrvang
-
Research Highlight |
Long-term dual antiplatelet therapy and bleeding in stable patients—insights from CHARISMA
- Joana Osório
-
News & Views |
Antihypertensive class matters for combination therapy
Combination therapy is used to lower blood pressure in the majority of patients with hypertension, yet there has been little evidence as to which classes of antihypertensive agents are most effective. The publication of findings from the ACCOMPLISH trial provides an opportunity to explore the merits of various combination therapies, with a focus on renal risk reduction.
- William B. White
The rise of the four-in-one pill?
Aortic plaque—dual therapy for a heterogeneous disease
Lackluster RUBY is received with some disappointment